Gastric Cancer Chemoresistance Mechanisms Revealed through CDK1-SOX9-BCL-xL Axis

Strategic Insights -

Researchers at the University of Miami have made a significant breakthrough in understanding the mechanisms behind chemoresistance in gastric cancer. Their study, published in the Journal of Experimental & Clinical Cancer Research, identifies a crucial CDK1-SOX9-BCL-xL signaling axis that drives chemoresistance in gastric cancer patients. This axis is overexpressed in gastric cancer cells, making them resistant to chemotherapy. The study also found that genetic knockdown and pharmacological inhibition of CDK1 suppressed SOX9 protein levels and transcriptional activity, restoring sensitivity to chemotherapy.

Key Takeaways:

  • The CDK1-SOX9-BCL-xL axis is a key mediator of chemoresistance in gastric cancer, with concurrent overexpression of CDK1 and SOX9 observed in gastric cancer patients.
  • Genetic knockdown and pharmacological inhibition of CDK1 suppressed SOX9 protein levels and transcriptional activity, restoring sensitivity to chemotherapy.
  • The study identified a miR-145-dependent epigenetic axis, where CDK1-mediated phosphorylation and activation of DNMT1 drive methylation-dependent silencing of miR-145, thereby relieving miR-145's repression of SOX9.
  • BCL-xL was found to be a direct transcriptional target of SOX9, functionally mediating cisplatin resistance.
  • CDK1 inhibition using dinaciclib re-sensitized resistant models to cisplatin by disrupting the CDK1-SOX9-BCL-xL pathway.

Statistics:

  • Gastric carcinoma ranks as the fifth most common cause of cancer-related mortality globally.
  • 44.1% of gastric cancer patients develop chemoresistance, leading to poor survival outcomes.
  • The CDK1-SOX9-BCL-xL axis is overexpressed in at least 75% of gastric cancer cells.
  • In vitro models were used to analyze the effects of CDK1 inhibition on SOX9 protein levels and transcriptional activity.
  • In vivo models, including patient-derived xenograft (PDX) models, were used to validate the therapeutic potential of CDK1 inhibition.

Sources:

  • CDK1 drives SOX9-mediated chemotherapeutic resistance in gastric cancer. Journal of Experimental & Clinical Cancer Research, 2025;44(1):284.
  • University of Miami, Department of Surgery, Miller School of Medicine, 1600 NW 10th Ave, Room 4007, Miami, FL 33136-1015, United States.